Molecular biomarkers for early-stage hepatocellular carcinoma: Clinical applications beyond alpha-fetoprotein
The International Journal of Biological Markers · 2026
DOI: 10.1177/03936155261476073 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The International Journal of Biological Markers, 2026. Verfasst von Marah Amer und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Biomarkers, Tumor, alpha-Fetoproteins. Die Arbeit nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related death worldwide, owing to late-stage diagnosis and underlying liver disease that limits curative treatment options. Conventional surveillance and diagnostic strategies relying on imaging and alpha-fetoprotein (AFP) lack sufficient sensitivity, particularly for early-stage disease, underscoring the need for more accurate and minimally invasive approaches. Liquid biopsy has emerged as a promising investigational approach for early HCC detection and disease monitoring by enabling analysis of tumor-derived components in circulation. This review summarizes recent advances in liquid biopsy biomarkers for early-stage HCC, including genomic alterations in circulating tumor DNA (ctDNA), DNA methylation markers, circulating microRNAs, exosome-derived non-coding RNAs, and inflammatory markers. Established biomarkers such as AFP, together with complementary biomarkers including PIVKA-II, contribute to HCC risk assessment, while ctDNA alterations, particularly TERT promoter and TP53 mutations, provide insight into early tumorigenesis and molecular heterogeneity. Aberrant methylation of tumor suppressor genes, including RASSF1A , SEPT9 , and CDKN2A , represents early molecular events detectable in plasma. Circulating and exosomal microRNAs and long non-coding RNAs (lncRNAs) have demonstrated potential to improve diagnostic accuracy, particularly when incorporated into multi-marker panels. Importantly, these biomarkers vary in their level of clinical validation, ranging from guideline-integrated markers to emerging candidates that still require further standardization and prospective validation. Integrating validated biomarkers with novel epigenetic and RNA-based signatures holds substantial promise for improving early detection, patient stratification, and therapeutic decision-making in HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
- Basic and Translational Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
- Gastroenterology/Multivisceral Transplant Unit, Padua University Hospital, Padova, Italy.
ORCID-Profile: Marah Amer, Valeria Tosello, Elisa Pinto
Zitieren
APA
Amer, M., Tosello, V., & Pinto, E. (2026). Molecular biomarkers for early-stage hepatocellular carcinoma: Clinical applications beyond alpha-fetoprotein. The International Journal of Biological Markers. https://doi.org/10.1177/03936155261476073
Vancouver
Amer M, Tosello V, Pinto E. Molecular biomarkers for early-stage hepatocellular carcinoma: Clinical applications beyond alpha-fetoprotein. The International Journal of Biological Markers. 2026. doi:10.1177/03936155261476073
BibTeX
@article{Amer2026,
author = {Amer, Marah and Tosello, Valeria and Pinto, Elisa},
title = {Molecular biomarkers for early-stage hepatocellular carcinoma: Clinical applications beyond alpha-fetoprotein},
journal = {The International Journal of Biological Markers},
year = {2026},
doi = {10.1177/03936155261476073}
}
EUVIMED